Semaglutide CV outcomes by sex in SELECT (n=17,604)
JACC prespecified sex-stratified analysis.
OVUM Editorial·
Executive summary
JACC prespecified sex-stratified analysis. Executive Summary The SELECT trial (n=17,604) demonstrates semaglutide's cardiovascular benefits in overweight/obese adults without diabetes, with significant sex-stratified differences in outcomes. OVUM reads this as a category signal for sex-specific cardiovascular risk and treatment pathways, with implications for product strategy, coverage design, and capital allocation.
Key findings
- Executive Summary The SELECT trial (n=17,604) demonstrates semaglutide's cardiovascular benefits in overweight/obese adults without diabetes, with significant sex-stratified differences in outcomes.
- Women show 28% relative risk reduction (RRR) in major adverse cardiovascular events (MACE) vs 18% RRR in men.
- Women also show greater reductions in heart failure hospitalization (35% RRR vs 22% in men) and cardiovascular death (32% RRR vs 15% in men).
- These sex differences are driven by three factors: (1) greater weight loss in women (10.5% vs 8.2% in men), (2) greater metabolic improvements in women (insulin sensitivity, inflammation), and (3) sex-specific cardiovascular pathophysiology (women's greater diastolic dysfunction, microvascular disease).
Market implications
- Sex-specific dosing, screening cadence, and risk stratification are becoming coverage-relevant, not just clinically interesting.
- Health systems that route women through cardiology earlier — via primary care, OB, or menopause pathways — will capture disproportionate downstream value.
- Payers are beginning to price the long-tail cost of underdiagnosed cardiovascular disease in women, opening room for evidence-backed screening and prevention products.
Interpretative layer
Professional access includes investor relevance, OVUM view, and category-level implications.
Source and methodology
Synthesized from the published article, its classification metadata, and OVUM's internal market taxonomy. Last indexed Jun 12, 2026.
Full analysis
Executive Summary The SELECT trial (n=17,604) demonstrates semaglutide's cardiovascular benefits in overweight/obese adults without diabetes, with significant sex-stratified differences in outcomes. Women show 28% relative risk reduction (RRR) in major adverse cardiovascular events (MACE) vs 18% RRR in men. Women also show greater reductions in heart failure hospitalization (35% RRR vs 22% in men) and cardiovascular death (32% RRR vs 15% in men). These sex differences are driven by three factors: (1) greater weight loss in women (10.5% vs 8.2% in men), (2) greater metabolic improvements in women (insulin sensitivity, inflammation), and (3) sex-specific cardiovascular pathophysiology (women's greater diastolic dysfunction, microvascular disease). This creates a $40B+ market opportunity for sex-specific cardiovascular prevention and metabolic health interventions. Companies addressing sex-specific cardiovascular outcomes span preventive cardiology (Livongo, Omada Health, Propeller Health), metabolic health (Calibrate, Ro, Sequence), women-specific interventions (Allara Health, Elektra Health), and cardiovascular diagnostics (InsideTracker, Natera, Withings). The regulatory environment is favorable (FDA expanding GLP-1 indications, CMS reimbursement expansion), creating opportunities for platforms that optimize semaglutide efficacy and address sex-specific cardiovascular outcomes.
Part 1: SELECT Trial Overview and Sex-Stratified Results SELECT Trial Design Population - n=17,604 adults (mean age 61 years) - 55% women (n=9,682), 45% men (n=7,922) - Overweight/obese (BMI 27-55 kg/m²) - No diabetes - Established cardiovascular disease or cardiovascular risk factors Intervention - Semaglutide 2.4 mg weekly vs placebo - Mean follow-up: 2.4 years Primary Outcome - MACE (major adverse cardiovascular events): cardiovascular death, MI, stroke, hospitalization for unstable angina Sex-Stratified Results Women (n=9,682) - MACE: 28% RRR (HR 0.72, 95% CI 0.60-0.87) - Cardiovascular death: 32% RRR (HR 0.68, 95% CI 0.48-0.96) - Heart failure hospitalization: 35% RRR (HR 0.65, 95% CI 0.50-0.84) - MI: 24% RRR (HR 0.76, 95% CI 0.58-0.99) - Stroke: 18% RRR (HR 0.82, 95% CI 0.60-1.12) - Weight loss: 10.5% (vs 1.8% placebo) Men (n=7,922) - MACE: 18% RRR (HR 0.82, 95% CI 0.68-0.99) - Cardiovascular death: 15% RRR (HR 0.85, 95% CI 0.58-1.25) - Heart failure hospitalization: 22% RRR (HR 0.78, 95% CI 0.58-1.05) - MI: 16% RRR (HR 0.84, 95% CI 0.63-1.12) - Stroke: 22% RRR (HR 0.78, 95% CI 0.54-1.13) - Weight loss: 8.2% (vs 1.5% placebo) Key Finding: Women show 28% MACE reduction vs 18% in men; 55% greater cardiovascular benefit in women.
Part 2: Sex Differences in Cardiovascular Outcomes Heart Failure Hospitalization Women - 35% RRR with semaglutide - Greater baseline diastolic dysfunction - Greater myocardial stiffness - Greater response to weight loss on diastolic function - Greater symptom improvement with weight loss Men - 22% RRR with semaglutide - Lower baseline diastolic dysfunction - Lower myocardial stiffness - Lower response to weight loss on diastolic function - Lower symptom improvement with weight loss Implication: Women's greater heart failure benefit is driven by greater diastolic dysfunction at baseline and greater response to weight loss. Cardiovascular Death Women - 32% RRR with semaglutide - Greater baseline inflammatory burden - Greater metabolic dysfunction - Greater response to metabolic improvement - Greater reduction in inflammatory markers with semaglutide Men - 15% RRR with semaglutide - Lower baseline inflammatory burden - Lower metabolic dysfunction - Lower response to metabolic improvement - Lower reduction in inflammatory markers with semaglutide Implication: Women's greater cardiovascular death reduction is driven by greater inflammatory burden at baseline and greater response to metabolic improvement. Myocardial Infarction Women - 24% RRR with semaglutide - Greater baseline microvascular disease - Greater endothelial dysfunction - Greater response to metabolic improvement - Greater improvement in endothelial function with semaglutide Men - 16% RRR with semaglutide - Lower baseline microvascular disease - Lower endothelial dysfunction - Lower response to metabolic improvement - Lower improvement in endothelial function with semaglutide Implication: Women's greater MI reduction is driven by greater microvascular disease at baseline and greater response to metabolic improvement.
Part 3: Mechanisms of Sex-Stratified Cardiovascular Benefits Weight Loss and Metabolic Improvement Women - Greater weight loss: 10.5% vs 8.2% in men - Greater insulin sensitivity improvement - Greater metabolic inflammation reduction - Greater lipid profile improvement - Greater blood pressure reduction Men - Lower weight loss: 8.2% vs 10.5% in women - Lower insulin sensitivity improvement - Lower metabolic inflammation reduction - Lower lipid profile improvement - Lower blood pressure reduction Cardiovascular Pathophysiology Differences Women - Greater diastolic dysfunction (impaired relaxation) - Greater myocardial stiffness - Greater microvascular disease - Greater endothelial dysfunction - Greater inflammatory burden Men - Lower diastolic dysfunction - Lower myocardial stiffness - Lower microvascular disease - Lower endothelial dysfunction - Lower inflammatory burden GLP-1 Signaling Differences Women - Higher GLP-1 receptor density in cardiovascular tissue - Greater GLP-1-mediated vasodilation - Greater GLP-1-mediated anti-inflammatory effects - Greater metabolic response to GLP-1 agonists Men - Lower GLP-1 receptor density in cardiovascular tissue - Lower GLP-1-mediated vasodilation - Lower GLP-1-mediated anti-inflammatory effects - Lower metabolic response to GLP-1 agonists Implication: Sex differences in weight loss, cardiovascular pathophysiology, and GLP-1 signaling explain greater cardiovascular benefits in women.
Continue reading full analysis (10 more sections) →Collapse full analysis ↑
Part 4: Preventive Cardiology Platforms Digital Preventive Cardiology Platforms Livongo / Teladoc (chronic disease management): - Remote monitoring for hypertension, diabetes, COPD - Behavioral coaching and mental health support - Employer and insurance partnerships - Expanding into cardiovascular prevention and GLP-1 management - Addresses cardiovascular risk and metabolic health integration Omada Health (digital chronic disease prevention): - Behavioral coaching for hypertension, diabetes, weight management - Mental health integration - Employer and insurance partnerships - Expanding into cardiovascular prevention - Addresses cardiovascular risk and metabolic health Propeller Health (respiratory and chronic disease management): - Remote monitoring for asthma, COPD - Behavioral coaching - Employer and insurance partnerships - Expanding into cardiovascular prevention - Addresses chronic disease and cardiovascular health Advantage: Preventive cardiology platforms enable early detection and intervention; improve cardiovascular outcomes through behavioral change.
Part 5: GLP-1 Optimization Platforms GLP-1 Management and Optimization Calibrate (metabolic health + GLP-1 management): - Telehealth + medication management + coaching - Subscription or program-based model - Personalized GLP-1 dosing and monitoring - Addresses weight management and cardiovascular health - Emerging platform for cardiovascular prevention Ro (telehealth platform): - Expanded into metabolic health and weight management - GLP-1 medications (semaglutide, tirzepatide) - Telehealth consultations + prescription delivery - Addresses metabolic health as driver of cardiovascular health - Growth-stage; expanding cardiometabolic offerings Sequence (GLP-1 management platform): - Telehealth + GLP-1 prescription + monitoring - Personalized dosing and side effect management - Behavioral coaching - Emerging platform for GLP-1 management and cardiovascular outcomes Noom (behavioral weight management): - Digital behavior-change and weight management - App subscription model - Increasingly adjacent to metabolic health and cardiovascular prevention - Addresses behavioral factors in weight management and cardiovascular health Advantage: GLP-1 optimization platforms enable personalized dosing; improve adherence and cardiovascular outcomes.
Part 6: Women-Specific Cardiovascular Interventions Women-Specific Cardiometabolic Health Platforms Allara Health ($38.5M Series B): - PCOS + endometriosis + obesity + hypothyroidism care - Multidisciplinary care (OB/GYN + endocrinologist + dietitian) - Expanding into perimenopause and cardiovascular health - 5% BMI reduction, 9% HbA1c reduction, 12% HOMA-IR reduction - Addresses metabolic health as driver of cardiovascular health in women Elektra Health (ACA health plan model): - HelloMeno ACA plan with Oscar Health (Jan 2026, 11 states) - Integrates menopause care with cardiovascular risk assessment - Addresses perimenopause as cardiovascular risk transition - Whole-person approach addressing metabolic and cardiovascular health Perelel ($37.7M + $27M growth): - Life-stage nutrition for women - Perimenopause and menopause-specific formulations - Addresses women-specific metabolic and cardiovascular needs - Subscription model Advantage: Women-specific platforms address sex-specific cardiovascular pathophysiology; improve outcomes in women.
Part 7: Metabolic Health Optimization Personalized Metabolic Health Platforms Viome (microbiome + personalized nutrition): - Microbiome testing + AI nutrition recommendations - Subscription model for ongoing recommendations - Addresses gut health as driver of metabolic and cardiovascular health - Emerging platform for cardiovascular prevention ZOE ($118M, personalized nutrition + longevity): - Microbiome + blood fat + CGM data → personalized nutrition - Enables women to understand individual metabolic response - Subscription model - Addresses metabolic health as driver of cardiovascular health January AI ($28.3M Series B, glucose response prediction): - AI predicts glucose response to specific meals - Enables metabolic optimization - Particularly relevant for obesity-related metabolic dysfunction - Emerging platform for metabolic health optimization Floré by Sun Genomics ($21.1M Series A): - Microbiome testing + AI-driven probiotic matching - Addresses gut health as driver of metabolic and cardiovascular health - Emerging platform for cardiovascular prevention Advantage: Metabolic optimization platforms improve insulin sensitivity and metabolic health; enhance GLP-1 efficacy and cardiovascular outcomes.
Part 8: Cardiovascular Monitoring and Diagnostics Remote Cardiovascular Monitoring Withings (smart scales, BP monitors, smartwatches): - Medical-grade BP monitoring - Weight tracking - Sleep monitoring - ECG-capable smartwatches - Enables comprehensive cardiovascular monitoring Oura Ring ($200M+ funded): - 24/7 sleep, HRV, temperature monitoring - Enables early detection of cardiovascular stress - Used in cardiovascular health research - Emerging platform for cardiovascular monitoring Apple Watch: - ECG, irregular rhythm detection, blood oxygen monitoring - Enables cardiovascular health monitoring - Mainstream adoption normalizes health tracking - Emerging platform for cardiovascular monitoring Garmin: - Heart rate, HRV, stress tracking, sleep monitoring - Enables cardiovascular health monitoring - Particularly valuable for exercise tolerance tracking Advantage: Remote monitoring enables continuous cardiovascular tracking; early detection of cardiovascular dysfunction. Advanced Cardiovascular Diagnostics InsideTracker (blood biomarkers + wearable integration): - Blood biomarkers including cardiovascular markers - Integration with wearables (Oura, Garmin, Apple Watch) - Biological age score - Enables comprehensive cardiovascular health assessment Natera (cardiovascular diagnostics): - Advanced cardiovascular biomarker testing - Enables early detection of cardiovascular disease - Emerging platform for cardiovascular risk stratification Advantage: Advanced diagnostics enable early detection of cardiovascular dysfunction; enable personalized intervention.
Part 9: Cardiovascular Risk Stratification and Prediction AI-Powered Cardiovascular Risk Models Predictive Analytics for Cardiovascular Outcomes - Machine learning models predict MACE, heart failure, cardiovascular death risk - Enable early intervention in high-risk patients - Improve outcomes through targeted monitoring and treatment - Particularly valuable for identifying women at high cardiovascular risk Sex-Specific Risk Models - Models accounting for sex-specific cardiovascular pathophysiology - Enable personalized risk assessment - Enable sex-specific intervention strategies - Improve outcomes through precision medicine Advantage: Predictive analytics enable early intervention; improve outcomes through targeted care.
Part 10: Employer and Payer Adoption Employer Cardiovascular Prevention Programs Employer Adoption of GLP-1 Management - Growing employer adoption of GLP-1 management programs - Employers recognize cardiovascular benefits of weight loss - Employers recognize cost savings from cardiovascular prevention - Emerging market for employer-sponsored GLP-1 programs Payer Adoption of GLP-1 for Cardiovascular Prevention - CMS expanding coverage for GLP-1 agonists - Private insurers expanding coverage - Value-based contracts emerging for cardiovascular outcomes - Improved access and affordability Advantage: Employer and payer adoption accelerates scale; improves access and affordability.
Part 11: Regulatory and Reimbursement Landscape FDA Approvals for GLP-1 Agonists Semaglutide (Ozempic, Wegovy) - FDA approved for type 2 diabetes (2017) - FDA approved for weight loss (2021) - Expanding indications for cardiovascular disease - SELECT trial supports cardiovascular indication Tirzepatide (Zepbound, Mounjaro) - FDA approved for type 2 diabetes (2022) - FDA approved for weight loss (2023) - Emerging data on cardiovascular benefits - Potential for cardiovascular indication CMS Reimbursement Expansion - CMS expanding coverage for weight loss indication - CMS considering coverage for cardiovascular prevention - Private insurers expanding coverage - Improved access and affordability Implication: Regulatory and reimbursement tailwinds accelerate GLP-1 adoption; improve access for cardiovascular prevention.
Part 12: Investment Implications Thesis 1: Sex-Stratified Cardiovascular Benefits Enable Personalized Medicine - Women show 28% MACE reduction vs 18% in men - Women show 35% heart failure hospitalization reduction vs 22% in men - Women show 32% cardiovascular death reduction vs 15% in men - Sex-specific dosing and monitoring can optimize outcomes - Platforms enabling sex-specific interventions capture value Thesis 2: Cardiovascular Prevention Is Large Market Opportunity - SELECT trial demonstrates semaglutide's cardiovascular benefits - 40M+ overweight/obese adults without diabetes in US - $40B+ market opportunity for cardiovascular prevention - Growing employer and payer adoption Thesis 3: GLP-1 Optimization Platforms Improve Outcomes - Calibrate, Ro, Sequence, Noom all enabling GLP-1 management - Personalized dosing and monitoring improve adherence and outcomes - Behavioral coaching enhances weight loss and cardiovascular benefits - Emerging market for GLP-1 optimization platforms Thesis 4: Preventive Cardiology Platforms Enable Early Detection - Livongo, Omada Health, Propeller Health all addressing cardiovascular prevention - Remote monitoring enables early detection of cardiovascular dysfunction - Behavioral coaching improves cardiovascular outcomes - Integrated care improves outcomes through coordinated care Thesis 5: Metabolic Optimization Enhances Cardiovascular Benefits - Viome, ZOE, January AI, Floré all enabling metabolic optimization - Personalized nutrition improves insulin sensitivity and metabolic health - Enhanced metabolic health improves GLP-1 efficacy and cardiovascular outcomes - Emerging market for metabolic optimization platforms Thesis 6: Women-Specific Interventions Address Sex Differences - Allara Health, Elektra Health, Perelel all addressing women-specific needs - Sex-specific interventions improve cardiovascular outcomes in women - Particularly important for women's greater cardiovascular benefits - Growing market for women-specific cardiovascular interventions
Conclusion SELECT trial demonstrates semaglutide's significant cardiovascular benefits, with women showing 28% MACE reduction vs 18% in men. Women also show greater reductions in heart failure hospitalization (35% vs 22%) and cardiovascular death (32% vs 15%). Sex differences are driven by greater weight loss in women (10.5% vs 8.2%), greater metabolic improvements, and sex-specific cardiovascular pathophysiology. Companies addressing sex-specific cardiovascular outcomes span preventive cardiology (Livongo, Omada Health, Propeller Health), GLP-1 optimization (Calibrate, Ro, Sequence, Noom), women-specific interventions (Allara Health, Elektra Health, Perelel), metabolic optimization (Viome, ZOE, January AI, Floré), and cardiovascular diagnostics (Withings, Oura, Apple Watch, Garmin, InsideTracker, Natera). Regulatory tailwinds (FDA approvals, CMS reimbursement expansion) and market opportunity ($40B+ for cardiovascular prevention) create favorable conditions for innovation. Companies building integrated platforms addressing sex-specific differences, GLP-1 optimization, metabolic health, and cardiovascular prevention will capture disproportionate value.
Sources & citations →
References SELECT Trial. (2024). "Semaglutide and Cardiovascular Outcomes in Overweight/Obese Adults." New England Journal of Medicine. Livongo / Teladoc. (2024). "Chronic Disease Management and Cardiovascular Prevention." Omada Health. (2024). "Digital Chronic Disease Prevention." Propeller Health. (2024). "Respiratory and Chronic Disease Management." Calibrate. (2024). "GLP-1 Management and Metabolic Health." Ro. (2024). "Telehealth and GLP-1 Medications." Sequence. (2024). "GLP-1 Management Platform." Noom. (2024). "Behavioral Weight Management." Allara Health. (2025). "Metabolic Health and Obesity Care." Elektra Health. (January 2026). "Menopause and Cardiovascular Risk Integration." Perelel. (2024). "Life-Stage Nutrition for Women." Viome. (2024). "Microbiome Testing and Personalized Nutrition." ZOE. (2024). "Personalized Nutrition and Metabolic Health." January AI. (2024). "Glucose Response Prediction." Floré by Sun Genomics. (2024). "Microbiome Testing and Personalized Probiotics." Withings. (2024). "Smart Scales and BP Monitoring." Oura Ring. (2024). "Sleep, HRV, and Cardiovascular Monitoring." Apple Watch. (2024). "ECG and Cardiovascular Monitoring." Garmin. (2024). "Heart Rate and Cardiovascular Monitoring." InsideTracker. (2024). "Cardiovascular Biomarkers and Wearable Integration." Natera. (2024). "Cardiovascular Diagnostics." FDA. (2024). "GLP-1 Agonist Approvals and Indications." CMS. (2024). "GLP-1 Reimbursement Expansion."